Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab

Breki, Christina-Marina; Dimitrakopoulou-Strauss, Antonia; Hassel, Jessica; Theoharis, Theoharis; Sachpekidis, Christos; Pan, Leyun; Provata, Astero

doi:10.1186/s13550-016-0216-5

EJNMMI Research

Table 2 Analysis results for all patients

From: Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab

Patient no.	Age (years)	Sex (M/F)	Study	Treatment response	Fractal dimension	Average multifractal index	Matching results
P1	67	M	Early	^a	2.487	−0.064	Typ
			Late	^a	2.509	−0.030
			Final	PR	2.525	−0.095
P2	48	F	Early	PD (slow)	2.611	+0.043	Typ
			Late	MR	2.588	−0.029
			Final	MR	2.623	+0.013
P3	56	M	Early	^a	2.465	−0.119	Typ
			Late	^a	2.644	−0.015
			Final	PR	2.643	−0.135
P4	62	M	Early	PD	2.688	−0.108	Typ
			Late	MR	2.743	+0.003
			Final	PD	2.726	−0.104
P5	37	F	Early	PD (slow)	2.512	+0.181	Typ
			Late	PD (slow)	2.395	−0.308
			Final	PD (slow)	2.602	−0.127
P6	55	M	Early	PD	2.634	−0.024	Typ
			Late	PD	2.673	+0.174
			Final	PD	2.511	+0.150
P7	55	M	Early	PD	2.65	+0.077	Typ
			Late	SD	2.629	−0.024
			Final	PD	2.624	+0.053
P8	74	M	Early	PD (slow)	2.622	+0.01	Typ
			Late	SD	2.629	+0.11
			Final	PD	2.529	+0.13
P9	60	F	Early	PD	2.618	+0.016	Non-Typ+
			Late	PD	2.603	−0.14
			Final	PD	2.655	−0.124
P10	67	M	Early	SD	2.589	−0.065	Non-Typ
			Late	PD	2.633	−0.044
			Final	PD	2.652	−0.11
P11	56	M	Early	MR	2.453	−0.369	Typ
			Late	PD (slow)	2.719	+0.455
			Final	MR	2.4	+0.085
P12	55	M	Early	PD (slow)	2.637	+0.044	Typ
			Late	PD	2.591	+0.03
			Final	PD	2.56	+0.075
P13	71	M	Early	SD	2.653	−0.113	Typ
			Late	SD	2.676	+0.07
			Final	PR	2.683	−0.043
P14	36	M	Early	PD	2.616	+0.053	Typ
			Late	PD	2.613	+0.106
			Final	PD	2.523	+0.159
P15	55	M	Early	SD	2.593	−0.264	Non-Typ+
			Late	SD	2.707	+0.281
			Final	SD	2.575	0.017
P16	73	M	Early	SD	2.61	−0.075	Typ
			Late	PD (slow)	2.676	+0.063
			Final	PD (slow)	2.618	−0.012
P17	61	F	Early	PD (slow)	2.698	+0.001	Typ
			Late	PR	2.697	−0.033
			Final	PR	2.705	−0.031
P18	71	M	Early	PD	2.697	−0.031	Non-Typ+
			Late	PD	2.684	−0.047
			Final	PD	2.713	−0.078
P19	39	M	Early	PD (slow)	2.611	−0.036	Typ
			Late	SD	2.629	+0.088
			Final	PD (slow)	2.572	+0.052
P20	70	M	Early	PD	2.663	+0.045	Typ
			Late	PD	2.659	−0.021
			Final	PD	2.621	+0.024
P21	49	M	Early	MR	2.533	+0.012	Non-Typ
			Late	PD	2.518	−0.036
			Final	PD	2.556	−0.023
P22	66	M	Early	SD	2.572	−0.037	Typ
			Late	SD	2.561	+0.031
			Final	SD	2.582	−0.005
P23	75	M	Early	PR	2.68	+0.09	Non-Typ+
			Late	PD	2.609	+0.011
			Final	PD	2.651	+0.101
P24	67	M	Early	SD	2.687	+0.03	Non-Typ+
			Late	PD (slow)	2.67	−0.071
			Final	PD (slow)	2.741	−0.04
P25	65	F	Early	MR	2.48	−0.319	Typ
			Late	MR	2.699	+0.151
			Final	MR	2.614	−0.168
P26	73	F	Early	PR	2.65	−0.081	Non-Typ
			Late	PD	2.708	−0.07
			Final	PD	2.714	−0.151
P27	62	M	Early	PD	2.602	+0.021	Non-Typ+
			Late	PR	2.599	+0.047
			Final	PR	2.576	+0.069
P28	54	F	Early	PR	2.699	+0.129	Typ
			Late	PR	2.655	−0.187
			Final	PR	2.716	−0.058
P29	61	F	Early	PR	2.622	−0.019	Non-Typ
			Late	PR	2.632	−0.032
			Final	PR	2.651	−0.052
P30	53	M	Early	SD	2.544	+0.051	Typ
			Late	SD	2.534	−0.203
			Final	SD	2.676	−0.152
P31	78	F	Early	SD	2.588	+0.046	Non-Typ+
			Late	SD	2.554	−0.165
			Final	SD	2.633	−0.118
Healthy subject 1	69	F	–	–	2.69	–	–
Healthy subject 2	73	M	–	–	2.723	–	–

Early stage: study I → study II; late stage: study II → study III; final stage: study I → study III
Typ: correspondence between analysis results and treatment outcome data
Non-Typ: non-typical patient (unknown reasons)
Non-Typ+: non-typical patient due to unspecific findings
PR partial remission, SD stable disease, PD progressive disease, MR mixed response
^aNo treatment outcome data

Back to article page